Combined Use of the Adenosine A2A Antagonist KW-6002 with l -DOPA or with Selective D1 or D2 Dopamine Agonists Increases Antiparkinsonian Activity but Not Dyskinesia in MPTP-Treated Monkeys
- 30 April 2000
- journal article
- Published by Elsevier in Experimental Neurology
- Vol. 162 (2) , 321-327
- https://doi.org/10.1006/exnr.2000.7350
Abstract
No abstract availableKeywords
This publication has 27 references indexed in Scilit:
- COMT inhibitionNeurology, 1998
- Influence of COMT inhibition on levodopa pharmacology and therapyNeurology, 1998
- Amantadine as treatment for dyskinesias and motor fluctuations in Parkinson's diseaseNeurology, 1998
- The effect of tolcapone on levodopa pharmacokinetics is independent of levodopa/carbidopa formulationZeitschrift für Neurologie, 1998
- Entacapone improves motor fluctuations in levodopa‐ treated Parkinson's disease patientsAnnals of Neurology, 1997
- Distribution of adenosine A2 receptor mRNA in the human brainNeuroscience Letters, 1991
- Direct autoradiographic localization of adenosine A2 receptors in the rat brain using the A2-selective agonist, [3H]CGS 21680European Journal of Pharmacology, 1989
- Pathogenesis of dyskinesias in parkinson's diseaseAnnals of Neurology, 1989
- Practical Therapy of Parkinson's DiseaseSeminars in Neurology, 1987
- Subclasses of adenosine receptors in the central nervous system: Interaction with caffeine and related methylxanthinesCellular and Molecular Neurobiology, 1983